| abstract |
The present invention is an antibody targeting CLDN18.2, which comprises VL and / or VH, wherein the VL is the amino acid sequence of VL CDR1 set forth in SEQ ID NO: 11, SEQ ID NO: 12, VL represented by SEQ ID NO: 13. The amino acid sequence of CDR2 includes the amino acid sequence of VL CDR3 shown by SEQ ID NO: 14, and the VH is the amino acid sequence of VH CDR1 shown by SEQ ID NO: 15, the amino acid sequence of VH CDR2 shown by SEQ ID NO: 16, and SEQ ID NO: 17. An antibody comprising the amino acid sequence of VH CDR3 shown is disclosed. Also disclosed are bispecific antibodies targeting CLDN18.2, complexes of the antibodies, CAR molecules targeting CLDN18.2 and cells containing them, and their use. |